Our finding that FXR genetic variants are associated with IBD, together with prior observations on FXR expression being altered in Crohn’s disease [56] and on FXR promoting intestinal barrier integrity [27] and antibacterial defence [26], further emphasizes the potential benefits of FXR ligand administration also in IBD. The gene discussed is NR1H4; the disease is Crohn disease.